NO20033737L - PEG-konjugater av HGT-NK4 - Google Patents

PEG-konjugater av HGT-NK4

Info

Publication number
NO20033737L
NO20033737L NO20033737A NO20033737A NO20033737L NO 20033737 L NO20033737 L NO 20033737L NO 20033737 A NO20033737 A NO 20033737A NO 20033737 A NO20033737 A NO 20033737A NO 20033737 L NO20033737 L NO 20033737L
Authority
NO
Norway
Prior art keywords
hgt
peg conjugates
conjugates
peg
Prior art date
Application number
NO20033737A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033737D0 (no
Inventor
Michael Brandt
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20033737D0 publication Critical patent/NO20033737D0/no
Publication of NO20033737L publication Critical patent/NO20033737L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20033737A 2001-02-23 2003-08-22 PEG-konjugater av HGT-NK4 NO20033737L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01104640A EP1234583A1 (en) 2001-02-23 2001-02-23 PEG-conjugates of HGF-NK4
PCT/EP2002/001837 WO2002074344A2 (en) 2001-02-23 2002-02-21 Peg-conjugates of hgt-nk4

Publications (2)

Publication Number Publication Date
NO20033737D0 NO20033737D0 (no) 2003-08-22
NO20033737L true NO20033737L (no) 2003-10-21

Family

ID=8176596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033737A NO20033737L (no) 2001-02-23 2003-08-22 PEG-konjugater av HGT-NK4

Country Status (27)

Country Link
US (2) US20030012775A1 (cs)
EP (2) EP1234583A1 (cs)
JP (2) JP2004521139A (cs)
KR (2) KR20030072629A (cs)
CN (1) CN100339393C (cs)
AR (1) AR032574A1 (cs)
AU (1) AU2002233354B2 (cs)
BG (1) BG108125A (cs)
BR (1) BR0207510A (cs)
CA (1) CA2438308A1 (cs)
CZ (1) CZ20032511A3 (cs)
EC (1) ECSP034741A (cs)
GT (1) GT200200038A (cs)
HR (1) HRP20030659A2 (cs)
HU (1) HUP0400979A2 (cs)
IL (1) IL157426A0 (cs)
MA (1) MA26998A1 (cs)
MX (1) MXPA03007130A (cs)
NO (1) NO20033737L (cs)
PA (1) PA8540501A1 (cs)
PE (1) PE20020992A1 (cs)
PL (1) PL367402A1 (cs)
RU (1) RU2293574C2 (cs)
SK (1) SK11652003A3 (cs)
WO (1) WO2002074344A2 (cs)
YU (1) YU65103A (cs)
ZA (1) ZA200306080B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
WO2004085471A2 (en) * 2003-03-24 2004-10-07 Novo Nordisk A/S Glp-2 derivatives
JP2007525981A (ja) 2004-03-03 2007-09-13 エフ．ホフマン−ラ　ロシュ　アーゲー 肝細胞成長因子のｎ末端フラグメントを組み換え発現するための方法
JP4511589B2 (ja) 2004-03-03 2010-07-28 エフ．ホフマン−ラ ロシュ アーゲー 肝細胞成長因子のｎ末端フラグメントを精製するための方法
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
JP5579164B2 (ja) * 2008-04-09 2014-08-27 ビロメッド カンパニー， リミテッド 凍結乾燥ｄｎａ製剤、組成物、及び凍結乾燥ｄｎａ製剤を製造する方法
CN102399293B (zh) * 2008-06-03 2013-12-04 中国科学院遗传与发育生物学研究所 一种与纤维蛋白特异结合的重组蛋白及其应用
US10532020B2 (en) 2012-08-22 2020-01-14 Revlon Consumer Products Corporation Nail coatings having enhanced adhesion
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
JPWO2020158690A1 (ja) * 2019-01-28 2021-12-16 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体
BR112021012472A2 (pt) * 2019-01-28 2021-11-30 Toray Industries Forma modificada por polietileno glicol de um fator de crescimento de hepatócito ou um fragmento ativo do mesmo, e, medicamento

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE222603T1 (de) 1992-05-18 2002-09-15 Genentech Inc Hepatozytwachstumfaktor variante
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
GEP20002180B (en) * 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
RU2158603C2 (ru) * 1994-05-31 2000-11-10 Амген Инк. Способы и препараты для стимулирования роста и дифференцировки мегакариоцитов
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
EP0816381B1 (en) * 1995-03-10 2004-01-14 NAKAMURA, Toshikazu Polyethylene glycol modified hepatocyte growth factor (hgf)
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
ATE342729T1 (de) 1997-01-15 2006-11-15 Phoenix Pharmacologics Inc Modifizierter tumor-nekrosefaktor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
EE05214B1 (et) * 1998-04-28 2009-10-15 Applied Research Systems ARS Holding N.V. Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2002233230B2 (en) * 2000-12-20 2007-02-01 F. Hoffmann-La Roche Ag Erythropoietin conjugates

Also Published As

Publication number Publication date
BR0207510A (pt) 2004-07-27
ECSP034741A (es) 2003-10-28
EP1234583A1 (en) 2002-08-28
HRP20030659A2 (en) 2004-08-31
HUP0400979A2 (hu) 2004-08-30
RU2003127395A (ru) 2005-03-20
MA26998A1 (fr) 2004-12-20
ZA200306080B (en) 2004-11-23
CZ20032511A3 (en) 2004-03-17
CN1571679A (zh) 2005-01-26
MXPA03007130A (es) 2003-11-18
CA2438308A1 (en) 2002-09-26
PL367402A1 (en) 2005-02-21
JP2010174034A (ja) 2010-08-12
US20030012775A1 (en) 2003-01-16
EP1389132A2 (en) 2004-02-18
NO20033737D0 (no) 2003-08-22
SK11652003A3 (sk) 2004-05-04
BG108125A (bg) 2004-09-30
CN100339393C (zh) 2007-09-26
US20080085857A1 (en) 2008-04-10
RU2293574C2 (ru) 2007-02-20
JP2004521139A (ja) 2004-07-15
KR20030072629A (ko) 2003-09-15
GT200200038A (es) 2002-09-30
IL157426A0 (en) 2004-03-28
PA8540501A1 (es) 2002-09-30
WO2002074344A2 (en) 2002-09-26
YU65103A (sh) 2006-03-03
US7846896B2 (en) 2010-12-07
AR032574A1 (es) 2003-11-12
PE20020992A1 (es) 2002-11-01
KR20090020713A (ko) 2009-02-26
AU2002233354B2 (en) 2006-11-30
WO2002074344A3 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
EE200300416A (et) Ravimvorm
DK1390066T3 (da) Vaccinesammensætning
ATE319451T1 (de) Tetrahydrochinolin-derivate
EP1441129A4 (en) TURBO PUMP
NO20040125L (no) Enterale formuleringer
DE50208638D1 (de) Katheter
NO20033737L (no) PEG-konjugater av HGT-NK4
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
DE50204386D1 (de) Kreuztransducer
DK1427444T3 (da) West-nil-vaccine
DE60214255D1 (de) Schlussstück
DE50204551D1 (de) Kugelgelenk
EE200300589A (et) Ravimkoostised
NO20033882D0 (no) Vaksine
IS2523B (is) Turn vindorkuvers
NO20041968L (no) Anvendelse av cystationin
DE50203984D1 (de) Kugelgelenk
DE60216881D1 (de) Schlupfbegrenztes Differential
EE200300480A (et) Pregabaliini-laktoosi konjugaadid
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
DE50200466D1 (de) Symmetrierübertrager
NO20035742D0 (no) Kjemisk modifisert progenipoietin konjugater
DE10107471B4 (de) Vitrine
DE60202381D1 (de) Paroxetin-n-formyl-derivate
DE60110464D1 (de) Federball

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application